Alnylam Pharmaceuticals, Inc. (ALNY)
174.00
-58.40
(-25.13%)
USD |
NASDAQ |
Oct 29, 16:00
175.30
+1.30
(+0.75%)
After-Hours: 06:49
Alnylam Pharmaceuticals Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 36.24M |
| March 31, 2026 | 15.71M |
| December 31, 2025 | 45.32M |
| September 30, 2025 | -448.35M |
| June 30, 2025 | 77.68M |
| March 31, 2025 | 46.08M |
| December 31, 2024 | 31.00M |
| September 30, 2024 | 102.76M |
| June 30, 2024 | 131.50M |
| March 31, 2024 | 28.91M |
| December 31, 2023 | 39.23M |
| September 30, 2023 | 33.14M |
| June 30, 2023 | 53.39M |
| March 31, 2023 | 46.37M |
| December 31, 2022 | 63.44M |
| September 30, 2022 | 297.02M |
| June 30, 2022 | 30.34M |
| March 31, 2022 | 34.96M |
| December 31, 2021 | 292.29M |
| September 30, 2021 | 573.84M |
| June 30, 2021 | 329.81M |
| March 31, 2021 | 51.18M |
| December 31, 2020 | 217.95M |
| September 30, 2020 | 34.15M |
| June 30, 2020 | 689.01M |
| Date | Value |
|---|---|
| March 31, 2020 | 53.87M |
| December 31, 2019 | 40.34M |
| September 30, 2019 | -20.70M |
| June 30, 2019 | 412.61M |
| March 31, 2019 | 390.93M |
| December 31, 2018 | 5.378M |
| September 30, 2018 | 12.99M |
| June 30, 2018 | 5.581M |
| March 31, 2018 | 41.52M |
| December 31, 2017 | 706.95M |
| September 30, 2017 | 28.92M |
| June 30, 2017 | 386.31M |
| March 31, 2017 | 2.716M |
| December 31, 2016 | 3.082M |
| September 30, 2016 | 4.346M |
| June 30, 2016 | 154.34M |
| March 31, 2016 | 16.07M |
| December 31, 2015 | 6.468M |
| September 30, 2015 | 3.651M |
| June 30, 2015 | 7.074M |
| March 31, 2015 | 598.98M |
| December 31, 2014 | 7.658M |
| September 30, 2014 | 4.794M |
| June 30, 2014 | 5.138M |
| March 31, 2014 | 718.88M |
Cash From Financing Definition
Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -412.29M |
| Vertex Pharmaceuticals, Inc. | -426.70M |
| BridgeBio Pharma, Inc. | -148.77M |
| Pfizer Inc. | -3.663B |
| Regeneron Pharmaceuticals, Inc. | -1.225B |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | 3.31% |